Oblenio
-
>$600M! Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune Disorders
Congratulations! This is the latest successful case of NewCo for China pharma and biotech companies
